Has Alberto Pinzon Ardila, MD received payments from drug or device companies?

Yes. Drug and device makers reported $350,682 in general payments to Alberto Pinzon Ardila, MD across 1,492 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alberto Pinzon Ardila, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alberto Pinzon Ardila, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alberto Pinzon Ardila, MD

Epilepsy · Miami, FLNPI 1154643120

Payments from drug & device makers

$350,682in general payments, 2019–2025

Across 1,492 payments — averaging $235.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

SK Life Science, Inc.$131K
Sunovion Pharmaceuticals Inc.$74K
UCB, Inc.$64K
Jazz Pharmaceuticals Inc.$38K
GW Research Limited$9K
Livanova USA, Inc.$8K
plus $25K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
SK Life Science, Inc.	106	$131,311
Sunovion Pharmaceuticals Inc.	64	$74,453
UCB, Inc.	202	$63,995
Jazz Pharmaceuticals Inc.	165	$37,832
GW Research Limited	2	$9,005
Livanova USA, Inc.	48	$8,445
AbbVie(2 entities)	183	$4,074
UCB SA	1	$2,689
Abbott	19	$1,973
Amgen	60	$1,385
Greenwich Biosciences, Inc.	37	$994
Teva Pharmaceuticals USA, Inc.	37	$978
Eisai Inc.	46	$974
Lilly USA, LLC	37	$849
Novartis	30	$744
Mallinckrodt Hospital Products Inc.	30	$631
Otsuka America Pharmaceutical, Inc.	12	$516
Neurocrine Biosciences, Inc.	36	$508
Neurelis, Inc.	19	$499
Pfizer	31	$483
EMD Serono, Inc.	4	$474
Lundbeck LLC	18	$471
AstraZeneca(2 entities)	12	$427
Harmony Biosciences LLC	11	$425
Argenx US, Inc.	10	$411
Adamas Pharmaceuticals, Inc.	33	$383
Almatica Pharma LLC	16	$371
Biohaven Pharmaceuticals, Inc.	12	$341
Tanabe Pharma America, Inc.	15	$326
Acorda Therapeutics, Inc	15	$276
Idorsia Pharmaceuticals US Inc	2	$244
Takeda Pharmaceuticals U.S.A., Inc.	9	$240
Kyowa Kirin, Inc.	12	$234
Biogen	9	$199
Neuropace, Inc.	3	$194
TG Therapeutics, Inc.	7	$179
Merz Pharmaceuticals, LLC	9	$176
Inspire Medical Systems, Inc.	1	$172
Sumitomo Pharma America, Inc.	7	$169
Scilex Pharmaceuticals Inc.	7	$169
Axsome Therapeutics, Inc.	6	$157
Immedica Pharma US, Inc.	2	$145
Johnson & Johnson(2 entities)	7	$145
Insightec,inc	1	$139
Amneal Pharmaceuticals LLC	7	$132
Aquestive Therapeutics, Inc.	7	$129
Biohaven Pharmaceutical Holding Company Ltd.	8	$126
Genentech USA, Inc.	5	$120
Octapharma USA, Inc.	5	$109
Zyla Life Sciences, Inc.	6	$99
Aprecia Pharmaceuticals, LLC	5	$97
Avadel CNS Pharmaceuticals, LLC	3	$89
Boston Scientific	3	$89
Supernus Pharmaceuticals, Inc.	4	$80
Avanir Pharmaceuticals, Inc.	5	$76
Averitas Pharma Inc.	2	$71
Banner Life Sciences, LLC	4	$68
Vanda Pharmaceuticals Inc.	3	$63
Avion Pharmaceuticals	4	$62
Upsher-smith Laboratories LLC	3	$54

How this compares

$350,682 in reported general payments places this provider in the 85th percentile of 23 epilepsy providers in Florida.

See all epilepsy providers in Florida →

Medicare billing

Part B allowed, 2024

$218,071

Medicare patients

423

Services billed

4,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other epilepsy in Miami

Andrew LermanMiami$4.5M
Miguel Melo-BicchiMiami$44K
Carlos MillanMiami$7K
Luis TornesMiami$6K
Gisela Moreira EyngMiami$3K
Brian CostellBoca Raton$4M
William TatumJacksonville$574K
Yue WangGainesville$45K
Jaivir RathoreOrlando$38K
Dipali NemadeOrlando$38K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →